BLACKSMITH MEDICINES, INC. — National Institutes of Health award 75N93022C00060 — The Wave

Recent Stories

Keeping the Human in Medicine: Two AI CoLab Researchers on What Machines Can’t ReplaceSomeone Is Hacking the Freezers. Pay Attention.Thinking of Running in 2028? Start HereWhat the Lame Duck Session Has to Do With the Ultimate 21st-Century Power Tool: RobotsBlack October Wasn't an Attack Wave. It Was a Warning.Extreme Ownership Means Ultimate Achievement – NASA Culture Shift

← Back to the board

Opportunity · Award

BLACKSMITH MEDICINES, INC. — National Institutes of Health award 75N93022C00060

Department of Health and Human Services

Federal funding for novel antibiotics against drug-resistant bacteria (ASPR/BARDA antimicrobial resistance countermeasures)

At a glance

Value: $14.6M obligated
Awarded to: Blacksmith Medicines, Inc.

Lifecycle

1 notice

AwardNational Institutes of HealthSep 20NIH awarded Blacksmith Medicines contract 75N93022C00060 for development of FG-2101, an LpxC inhibitor for MDR gram-negative urinary tract infections.$14.6M obligated75N93022C00060Blacksmith Medicines, Inc.BiotechLifecycle 17 linked

Analytics cookies help us see how the site is used. They only run if you accept. Privacy Policy

BLACKSMITH MEDICINES, INC. — National Institutes of Health award 75N93022C00060 — The Wave